DE69837095D1 - Fluorierung von proteinen und peptiden für positronemissionstomographie - Google Patents

Fluorierung von proteinen und peptiden für positronemissionstomographie

Info

Publication number
DE69837095D1
DE69837095D1 DE69837095T DE69837095T DE69837095D1 DE 69837095 D1 DE69837095 D1 DE 69837095D1 DE 69837095 T DE69837095 T DE 69837095T DE 69837095 T DE69837095 T DE 69837095T DE 69837095 D1 DE69837095 D1 DE 69837095D1
Authority
DE
Germany
Prior art keywords
peptides
peptide
targeted
tissue
stomography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837095T
Other languages
English (en)
Other versions
DE69837095T2 (de
Inventor
L Griffiths
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DE69837095D1 publication Critical patent/DE69837095D1/de
Publication of DE69837095T2 publication Critical patent/DE69837095T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69837095T 1997-09-03 1998-09-03 Fluorierung von proteinen und peptiden für positronemissionstomographie Expired - Lifetime DE69837095T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5748597P 1997-09-03 1997-09-03
US57485P 1997-09-03
PCT/US1998/018268 WO1999011590A1 (en) 1997-09-03 1998-09-03 Fluorination of proteins and peptides for f-18 positron emission tomography

Publications (2)

Publication Number Publication Date
DE69837095D1 true DE69837095D1 (de) 2007-03-29
DE69837095T2 DE69837095T2 (de) 2007-11-22

Family

ID=22010853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837095T Expired - Lifetime DE69837095T2 (de) 1997-09-03 1998-09-03 Fluorierung von proteinen und peptiden für positronemissionstomographie

Country Status (8)

Country Link
US (3) US6187284B1 (de)
EP (1) EP1009726B1 (de)
JP (1) JP3992923B2 (de)
AT (1) ATE353864T1 (de)
AU (1) AU9375698A (de)
CA (1) CA2302360C (de)
DE (1) DE69837095T2 (de)
WO (1) WO1999011590A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
AU760854B2 (en) * 1998-06-22 2003-05-22 Immunomedics Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
DE10121741A1 (de) * 2001-05-04 2002-11-14 Forschungszentrum Juelich Gmbh Verfahren zur Synthese trägerarmer ·18·F markierter Verbindungen
CN101838289A (zh) * 2002-02-06 2010-09-22 约翰·霍普金斯大学 使用放射性同位素标示亲油性盐的用于线粒体机能障碍的非侵入性诊断显像技术
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CA2478924A1 (en) * 2002-03-14 2003-09-18 Qlt Inc. Cancer associated araf1 protein kinase and its uses
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
FR2841558B1 (fr) * 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
FR2841554B1 (fr) 2002-07-01 2008-01-18 Commissariat Energie Atomique Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules
WO2004110500A1 (en) * 2002-08-02 2004-12-23 Mallinckrodt Inc. Radioactively labelled amino acid analogues, their preparation and use
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
US7741524B2 (en) * 2003-04-22 2010-06-22 Solvay (Societe Anonyme) Iodinated organic substances of low molecular mass and process for preparing them
AU2004259769B2 (en) * 2003-07-24 2011-11-24 The Queen's Medical Center Preparation and use of alkylating agents
US20050175534A1 (en) * 2004-02-06 2005-08-11 Adam Michael J. Method of synthesizing compounds having a phosphorus-fluorine-18 bond
KR100808547B1 (ko) 2005-06-22 2008-02-29 재단법인서울대학교산학협력재단 펩타이드 수용체 영상용 제제로 사용할 수 있는 ｆ－１８－플로로벤질리덴하이드라존－니코틴아마이드－펩타이드 유도체 및 펩타이드에 방사성불소를 효율적으로 표지하기 위한 방법
US20070048803A1 (en) * 2005-08-25 2007-03-01 Lee Peter P Immune profiling of lymph nodes associated with cancer
US20070092907A1 (en) * 2005-10-21 2007-04-26 Gambhir Sanjiv S Methods of screening compound probes
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
US8940871B2 (en) * 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
CN101568352B (zh) * 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US8153100B2 (en) * 2007-01-11 2012-04-10 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8709382B2 (en) 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8202509B2 (en) * 2007-01-11 2012-06-19 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
JP6126773B2 (ja) * 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US8029743B2 (en) * 2007-09-19 2011-10-04 General Electric Company Microfluidic device with vertical injection aperture
WO2009123881A1 (en) * 2008-03-31 2009-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
JP5431476B2 (ja) * 2008-08-01 2014-03-05 アメリカ合衆国 Ａ３アデノシン受容体アンタゴニストおよびａ３アデノシン受容体部分アゴニスト
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US7927476B2 (en) * 2008-12-22 2011-04-19 General Electric Company Injection method for microfluidic chips
CN102448494B (zh) 2009-02-13 2016-02-03 免疫医疗公司 具有胞内可裂解的键的免疫共轭物
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
US8834839B2 (en) * 2009-04-27 2014-09-16 General Electric Company Labeled molecular imaging agents, methods of making and methods of use
EP2506876B1 (de) 2009-12-02 2016-10-12 Imaginab, Inc. J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
US8784774B2 (en) 2011-09-16 2014-07-22 General Electric Company Labeled molecular imaging agents and methods of use
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
US8937186B2 (en) 2012-08-21 2015-01-20 Uop Llc Acids removal and methane conversion process using a supersonic flow reactor
EP2774930A1 (de) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocenverbindungen und markierte Moleküle damit für In-vivo-Bildgebung
US9468692B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
US9468693B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
US20180037526A1 (en) * 2015-02-09 2018-02-08 The Trustees Of Princeton University Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
EP4137158A1 (de) 2015-08-07 2023-02-22 Imaginab, Inc. Gegen moleküle gerichtete antigenbindende konstrukte
JP6953444B2 (ja) 2016-05-19 2021-10-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｅｔイメージング用免疫修飾因子
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
CN115231995A (zh) * 2022-06-14 2022-10-25 上海应用技术大学 一种单氟二溴代丙酮衍生物及其制备与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729515B2 (en) * 1996-10-17 2001-02-01 Immunomedics Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system

Also Published As

Publication number Publication date
EP1009726B1 (de) 2007-02-14
US6358489B1 (en) 2002-03-19
JP3992923B2 (ja) 2007-10-17
JP2001515843A (ja) 2001-09-25
DE69837095T2 (de) 2007-11-22
ATE353864T1 (de) 2007-03-15
US20020119096A1 (en) 2002-08-29
AU9375698A (en) 1999-03-22
CA2302360A1 (en) 1999-03-11
US6187284B1 (en) 2001-02-13
EP1009726A1 (de) 2000-06-21
WO1999011590A1 (en) 1999-03-11
CA2302360C (en) 2005-11-15
US6953567B2 (en) 2005-10-11

Similar Documents

Publication Publication Date Title
DE69837095D1 (de) Fluorierung von proteinen und peptiden für positronemissionstomographie
Feldman et al. Model of alpha 2-macroglobulin structure and function.
DE69937899D1 (de) Antikörper-serumprotein hybride
BR0009323A (pt) Anticorpos humanos que ligam a il-12 humana e métodos para a produção
BRPI0412007A (pt) mutagênese look-through
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
SE7900662L (sv) Forfarande och reagens for immunoanalys
PT762901E (pt) Peptidos marcados com tecnecio-99m para imagiologia.
ATE325625T1 (de) Technetium-99m markierte peptide zur diagnostischen bilderzeugung von entzündungen
DK0570493T3 (da) Technetium-99m-mærkede polypeptider til billeddannelse.
KR900700886A (ko) 단백질의 방사선라벨링 방법
ATE237365T1 (de) Technetium-99-markierte peptide zur visualisierung vom entzuendungen
ATE152918T1 (de) Technetium-99m-markierte peptide zur bilderzeugung
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
DK499086A (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
PT749325E (pt) Mpleculas biespecificas possuindo utilidades clinicas
ATE468533T1 (de) Enzym-protein-komplex
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
Tong et al. Amino acid sequence of rabbit skeletal muscle myosin. 50-kDa fragment of the heavy chain.
BR0204937A (pt) Oligopeptìdeos para a promoção do crescimento capilar
Spolaore et al. Site-specific derivatization of avidin using microbial transglutaminase
CO4520255A1 (es) Terapia de tumores mediante linfocitos t citotoxicos de transferencia adoptivos especificos de cd44v
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
DE69611037T2 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition